Poland· PL-100417464
Ajovy
A fremanezumab product containing fremanezumabum, registered in Poland by TEVA GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Fremanezumab is registered in 15 of 19 countries.
Countries holding a registration under ATC N02CD03 (fremanezumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Fremanezumab · ATC N02CD03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Fremanezumabum
- Manufacturer
- TEVA GmbH
- Country
- Poland (PL)
- ATC code
- N02CD03
- ATC class
- Fremanezumab
- Defined daily dose
- 7.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991396497
- gtin05909991396503
- gtin05909991423605
- gtin05909991423612
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fremanezumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAJOVYTeva GmbH, Ulm
- SpainAJOVY 225 MG SOLUCION INYECTABLE EN JERINGA PRECARGADATeva Gmbh
- SwedenAJOVY 225 mg Injektionsvätska, lösning i förfylld injektionspennaTEVA GmbH
- BelgiumAjovy 225 mgTeva
- IcelandAJOVYTEVA GmbH
- NorwayAjovyTeva GmbH
- SwitzerlandAJOVY 225 mg, Injektionslösung im FertigpenTeva Pharma AG
- United StatesAJOVYTeva Pharmaceuticals USA, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ajovy
- Iceland · Ajovy
- Liechtenstein · Ajovy
- Norway · Ajovy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1d57718-3145-40ca-ad8f-4ff488f3dfd7 GET /v1/drugs/f1d57718-3145-40ca-ad8f-4ff488f3dfd7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "225 mg",
"packaging": "05909991396497 ¦ Rpz ¦ EU/1/19/1358/001 ¦ 131578\n1 amp.-strzyk. 1,5 ml\n05909991396503 ¦ Rpz ¦ EU/1/19/1358/002 ¦ 131579\n3 amp.-strzyk. 1,5 ml\n05909991423605 ¦ Rpz ¦ EU/1/19/1358/003 ¦ 135274\n1 wstrzykiwacz 1,5 ml\n05909991423612 ¦ Rpz ¦ EU/1/19/1358/004 ¦ 135275\n3 wstrzykiwacze 1,5 ml",
"substance": "Fremanezumabum 225 mg",
"common_name": "Fremanezumabum",
"pl_product_id": "100417464",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about fremanezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.